| Systemic Lupus Erythematosus Research | Lifetime | 2 | US 1 | 99.96 |
| Atherosclerosis and Cardiovascular Diseases | Lifetime | 6 | US 4 | 99.90 |
| Monoclonal and Polyclonal Antibodies Research | Lifetime | 18 | US 14 | 99.94 |
| Pregnancy and Medication Impact | Lifetime | 6 | US 5 | 99.75 |
| Reproductive System and Pregnancy | Lifetime | 19 | US 15 | 99.66 |
| Systemic Sclerosis and Related Diseases | Lifetime | 20 | US 8 | 99.69 |
| Drug-Induced Ocular Toxicity | Lifetime | 3 | US 2 | 99.31 |
| Renal Diseases and Glomerulopathies | Lifetime | 44 | US 22 | 99.58 |
| T-cell and B-cell Immunology | Lifetime | 142 | US 90 | 99.72 |
| Peripheral Neuropathies and Disorders | Lifetime | 38 | US 12 | 99.50 |
| Cytokine Signaling Pathways and Interactions | Lifetime | 83 | US 41 | 99.36 |
| Liver Diseases and Immunity | Lifetime | 71 | US 26 | 99.17 |
| Protein Tyrosine Phosphatases | Lifetime | 48 | US 27 | 97.93 |
| Platelet Disorders and Treatments | Lifetime | 219 | US 87 | 98.50 |
| Rheumatoid Arthritis Research and Therapies | Lifetime | 267 | US 79 | 98.89 |
| Pharmacological Effects of Natural Compounds | Lifetime | 347 | US 57 | 97.54 |
| Heparin-Induced Thrombocytopenia and Thrombosis | Lifetime | 118 | US 46 | 97.11 |
| Lipid metabolism and disorders | Lifetime | 251 | US 106 | 97.17 |
| Diabetes and associated disorders | Lifetime | 924 | US 356 | 96.88 |
| Blood disorders and treatments | Lifetime | 366 | US 148 | 95.91 |
| Complement system in diseases | Lifetime | 822 | US 316 | 93.95 |
| Aortic Thrombus and Embolism | Lifetime | 405 | US 164 | 77.24 |
| Systemic Lupus Erythematosus Research | 2021-2025 | 4 | US 3 | 99.78 |
| Monoclonal and Polyclonal Antibodies Research | 2021-2025 | 50 | US 20 | 98.68 |
| Atherosclerosis and Cardiovascular Diseases | 2021-2025 | 18 | US 6 | 98.28 |
| T-cell and B-cell Immunology | 2021-2025 | 177 | US 74 | 94.66 |
| Peripheral Neuropathies and Disorders | 2021-2025 | 144 | US 29 | 95.78 |
| Drug-Induced Ocular Toxicity | 2021-2025 | 18 | US 9 | 84.97 |
| Renal Diseases and Glomerulopathies | 2021-2025 | 603 | US 162 | 89.76 |
| Systemic Sclerosis and Related Diseases | 2021-2025 | 491 | US 99 | 88.04 |
| Reproductive System and Pregnancy | 2021-2025 | 658 | US 126 | 86.91 |
| Cytomegalovirus and herpesvirus research | 2021-2025 | 525 | US 204 | 83.89 |
| Pregnancy and Medication Impact | 2021-2025 | 379 | US 122 | 84.79 |
